Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

The advent of anti-TNF agents as the first approved targeted therapy in the treatment of
inflammatory bowel disease (IBD) patients has made a major impact on our existing …

Current inflammatory bowel disease (IBD) therapies are ineffective in a high proportion of
patients. Combining bulk and single-cell transcriptomics, quantitative histopathology and in …

A hallmark of the immune system is the interplay among specialized cell types transitioning
between resting and stimulated states. The gene regulatory landscape of this dynamic …

Inflammatory bowel disease (IBD) presents with disabling symptoms and may lead to
insufficient growth and late pubertal development in cases of disease onset during …

Bone remodeling is a lifelong process in vertebrates that relies on the correct balance
between bone resorption by osteoclasts and bone formation by osteoblasts. Bone loss and …

Across Europe, the genetics of the Chalcolithic/Bronze Age transition is increasingly
characterized in terms of an influx of Steppe-related ancestry. The effect of this major shift on …

Crohn's disease (CD) and ulcerative colitis (UC) are common intestinal bowel diseases
(IBD) characterized by intestinal epithelial injury including extensive epithelial cell death …

Ulcerative Colitis (UC) is a chronic idiopathic inflammatory bowel disease in which the
colon's lining becomes inflamed. Exploring herbal remedies that can recover mucosal …

Background Anti‐tumor necrosis factor‐α (TNF‐α) is used for the treatment of severe cases
of IBD, including Crohn's disease (CD) and ulcerative colitis (UC). However, one‐third of the …